1 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 2 Phase 3, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Terazosin (Hytrin): new trials by email Literature Review of Terazosin (Hytrin) trials Research Report on Terazosin (Hytrin)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Terazosin And Metabolic Engagement in Alzheimer's Disease Terazosin (Hytrin), Placebo - Alzheimer s Disease | Phase 2 | Not yet recruiting | Qiang Zhang | 100 | 2027-08-01 | 2026-09-01 |
| Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial Placebo, Telmisartan, Terazosin (Hytrin) - Parkinsons Disease (PD) | Phase 3 | Recruiting | University College, London | 1200 | 2025-09-12 | 2025-10-03 |
| Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up Doxazosin GITS (Cardura XL), Terazosin (Hytrin) - Prostatic Hyperplasia, Urinary Retention | Not applicable | Terminated | Hospital Authority, Hong Kong | 120 | 2005-10-01 | 2011-06-16 |
| Action to Control Cardiovascular Risk in Diabetes (ACCORD) Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin - Atherosclerosis, Cardiovascular Diseases | Phase 3 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 10251 | 1999-09-01 | 2016-11-22 |
Alzheimer Disease (1) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Coronary Disease (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Hypercholesterolemia (1) · Hypertension (1) · Parkinson Disease (1) · Prostatic Hyperplasia (1) · Urinary Retention (1)
Hospital Authority, Hong Kong (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Qiang Zhang (1) · University College, London (1)
United States (2) · Canada (1) · China (1) · United Kingdom (1)
Chi Wai Cheng, Dr (1) · Denise Simons-Morton, MD, PhD (1) · Prof Camille Carroll (1) · Prof Thomas Foltynie (1) · Qiang Zhang, MD (1) · Robert Byington, PhD (1) · William Friedewald, MD (1)
PMID 18539917, PMID 19898642, PMID 20061358, PMID 20061360, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20427682, PMID 20571135, PMID 20587587, PMID 20594588, PMID 21366473, PMID 21663644, PMID 21958949, PMID 22019270, PMID 22049171, PMID 22179956, PMID 22374637, PMID 22432114, PMID 22450889, PMID 22515638, PMID 22619083, PMID 22646230, PMID 22723577, PMID 23033246, PMID 23238658, PMID 23412077, PMID 23990163, PMID 24170759, PMID 24296848, PMID 24493100, PMID 24595629, PMID 24779562, PMID 25088437, PMID 25127725, PMID 25159234, PMID 25172198, PMID 25193529, PMID 25229335, PMID 25267796, PMID 25652389, PMID 25666468, PMID 25887355, PMID 26261902, PMID 26459421, PMID 26464212, PMID 26476086, PMID 26822326, PMID 27161620, PMID 27289122
N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1)